Abstrakt
YSF 2.0 is a conference aimed at young scientists and students below 35 years of age, specializing in oncology-related sciences (including basic sciences such as biology, medical physics, genetics, biotechnology, pharmacy), as well as young clinicians, pathomorphologists, medical physicists and radiographers interested in therapy and diagnostics.
The forum is an ideal place not only to present one's work but also to exchange professional experiences and form brand new international cooperation networks. The conference will be conducted in English in a hybrid form: on-line and on-site on the premises of the Greater Poland Cancer Centre.
The Forum is under the honorary scientific patronage of Professor Julian Malicki - the Director of the Greater Poland Cancer Centre.
The Forum has a competitive character. Abstracts submitted by participants will be evaluated by the Jury and reviewed by experts in basic and clinical sciences.
Bibliografia
P1 Andreea-Cosmina Ciobanu 3D-Printed Bolus for Total Scalp Irradiation: A case study of a 71-year-old woman with metastatic cancer
P2 Izabela Żółnowska Albumin-Based Nanoparticles as a Novel Approach for Systemic Lutein Delivery
P3 Katarzyna Wawrzyniak Comparison of the safety profiles of CDK4/6 inhibitors used in hormone receptor-positive breast cancer - a survey study
P4 Tomasz Przybylski Development and validation of the RP-HPLC method for quantitative determination of phytosterols in intravenous lipid emulsions
P5 Ewelina Majewska Development of 3D Cell Culture Models for Translational Research and Immunotherapy Studies
P6 Gabriela Karaszkiewicz Differential response of human acute myeloid leukemia cells to selective MCL-1 inhibitor S63845
P11 Agata Lewandowska Dosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy
P12 Marta Fischer Drug-related problems in oncologic patients based on retrospective analysis of medical records
P13 Joanna Uszko Efficacy of the combination of venetoclax and MAPK pathway inhibitor in acute myeloid leukemia cells
P14 Monika Rosochowicz Efficacy of the combination of venetoclax and MAPK pathway inhibitor in acute myeloid leukemia cells
P15 Katarzyna Wrzeszcz Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating DFS and OS
P16 Monika Bar Inhibition of HSF1 activity reduces the proliferation of estrogen-positive breast cancer cells and increases the effectiveness of hormone therapy
P17 Piotr Świerzewski Irradiation of uveal melanoma cells in 2D and 3D in vitro models
P18 Jagoda Szkudlarek Liposomal Delivery of Natural Compounds for Glioblastoma Multiforme Therapy: Stability and Cytotoxicity Analysis
P19 Karina Tylkowska lncRNA EGOT is the marker of HPV infection and a prognostic factor for HNSCC patients
P20 Katarzyna Dominiak Parenteral Nutrition Lipid Emulsions as Carriers for Cyanidin and Tangerine Oil
P21 Kamila Buzun Protein nanoparticles loaded with active compounds from Magnolia officinalis
P22 Patryk Niewinski Senescence in head and neck squamous cell carcinoma: link between senescence-associated secretory phenotype (SASP) expression and clinicopathological features
P23 Agata Pietrzak The drug development in Europe vs U.S.: special focus on Theranostics
P24 Julia Kozikowska The impact of hypoxia on m6A RNA signatures in HNSCC pathogenesis
P25 Luiza Czaczkowska The importance of Endocrine Disturbing Factors in relation to breast cancer- Review Case
P26 Patrycja Gnacek Verification of the usefulness of the VarianESAPI-EQD2Converter script in clinical practice
P27 Katarzyna Morańska What is the landscape of the uterine, vaginal, and gut microbiome in patients with gynecological cancers?
P28 Maciej Bulwa Assessment of genetic predisposition in patients with neuroendocrine pancreatic tumors, treated at the National Institute of Oncology, the Gliwice Branch
P29 Anna Olechnowicz Analysis of cancer-related differentially expressed genes in subcutaneous muscles of a Huntington's disease mouse model
P30 Pola Głowacka Assessment of postbiotics as radiotherapy adjunctive agents on glioblastoma in vitro models treated with ionizing radiation
P31 Marta Kropacz Cancer immunotherapy by activation of cGAS-STING and RIG-I/MAVS pathways with oligonucleotides delivered via functionalized silk nanospheres
P32 Patrycja Śliwa-Tytko Immunological disorders and incidence of infections in pediatric survivors of acute lymphoblastic leukemia (ALL) - a single-center study
P33 Ghina Tsurayya Integration of radiomic-based nomograms for prediction of axillary lymph node metastasis in breast cancer: A Systematic Review and Meta-Analysis
P34 Tomasz Chady Machine learning guided eccDNA prediction
P35 Natalia Gucwa Selective CDK2/5 Inhibitors: A Novel Approach to Developing Effective and Safe Glioma Therapies
P36 Grzegorz Matuszny Target Volume and Toxicity: Does a Larger Volume Mean Higher Toxicity in Prostate Cancer Radiotherapy?
P37 Maria Bocheńska What’s inside the uterus? The reveal of a healthy uterine microbiome composition
P38 Sławomir Woźniak The miRecc database containing miRNA sequences potentially encoded by eccDNA
P39 Maciej Skrzeszewski Cellular senescence and autophagy in colon cancer cell chemoresistance and stemness: role of hypoxic environment and autophagy inhibition
P40 Jakub Dobrosielski Optimization of high-pressure homogenization process of magnolol-enriched intravenous lipid emulsion
P41 Stanisław Kisiel Role of blood-brain barrier disruption in brain cancer development in stroke survivors
P42 Ewelina Nowak The influence of the length of the irradiated optical fiber on the Cherenkov radiation value during small-field dosimetry using Exradin W2 scintillators
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Bez utworów zależnych 4.0 Międzynarodowe.
Prawa autorskie (c) 2025 Zeszyty Naukowe Wielkopolskiego Centrum Onkologii